Juvelook vs Rejuran: Key Differences and How to Compare

You have heard Juvelook and Rejuran mentioned for firmness, fine lines and skin texture. Both are offered as injectable ways to address skin quality, but they are not identical skin boosters, and current evidence does not establish either as a consistent winner. Juvelook combines poly-D,L-lactic acid (PDLLA) particles with hyaluronic acid (HA); the base Rejuran product contains polynucleotides (PN) derived from salmon-family fish material. Your decision depends on the actual concern, exact formulation, injection plan, tolerability and willingness to recover.

If you want to remove deep folds, dramatically lift sagging tissues or change cheek volume, choosing between these two products may be the wrong starting question: a different anatomical assessment is needed. For superficial lines, uneven texture and skin surface quality, comparing the two approaches with a clinician may be useful, without assuming a guaranteed effect.

Juvelook vs Rejuran: differences that matter to your choice

In this comparison the word version is essential. Juvelook has formulations containing different amounts of material, including Volume, not simply a larger interchangeable dose for every treatment area. Rejuran also has differently formulated and positioned variants. The table therefore does not authorise substituting products merely because advertising groups them together. Milligrams of powder, millilitres of prepared solution and injected volume measure different things. You cannot fairly compare offers of 2 mL Juvelook and 2 mL Rejuran in price or expected effect without knowing the exact products and preparation.

Why can two offers quoting the same number of millilitres be so different?

A clinician may have a defensible reason to use a different volume or interval from a published protocol. It should be a clinical explanation, not a slogan about millilitres in an advertisement. Ask for an itemised cost for your actual concern, rather than an undefined beauty course.

Which skin concern makes the distinction meaningful?

Thin, reactive skin with small lines. PN studies suggest improvements in some skin characteristics, but do not establish one uniform way to treat everyone. That may make Rejuran worth discussing; it does not guarantee better comfort or efficacy for you. If you react strongly to products, assessing irritation and the skin barrier is more useful than simply choosing the brand promoted as most restorative.

Uneven texture and superficial post-inflammatory marks. Juvelook is of clinical interest as a combination of PDLLA and HA. But scars differ in depth and shape: depressions, firm scars, active acne and enlarged pores are not one diagnosis. Injections cannot be assumed to fix all of them. Treating active acne, considering a laser-based approach or targeting particular scars after examination may be more suitable than a vague skin-quality course.

Jowling or substantial volume loss. Neither product name means a surgical lift or predictable replacement of bony support. Ask a clinician to distinguish skin laxity, displaced fat compartments and missing volume. This helps explain why an injection aimed at superficial skin might fit one concern, while a very different approach—or no procedure—fits another.

Under-eye area. Thin skin, visible vessels, fluid retention and anatomical shadowing produce different appearances. Some product-specific studies in the region exist, but their findings cannot be transferred automatically to every concentration, technique or individual. Errors of product choice or injection depth can be especially conspicuous here. Arrange an anatomical assessment rather than following a social-media recommendation that everyone should have under-eye injections.

Has research established a winner?

The manufacturer describes the Korean Juvelook range as PDLLA combined with HA. A small study published in 2026 followed 20 people with nasolabial folds who received Juvelook. The authors reported improvement, but without direct comparison to Rejuran and with limited follow-up it cannot establish superiority. Other small Juvelook studies involve particular areas; their findings should not be applied uncritically to the entire face, other techniques or other formulations.

A 2025 systematic review of PN included nine studies with 219 participants; study quality was low to moderate. Findings concerning texture, wrinkles and elasticity were promising, but the authors called for stronger studies. A separate 2026 review of randomised PN/PDRN trials included seven studies and 183 participants across different skin and healing problems, with markedly different protocols. In a separate randomised study of 72 participants, Rejuran was injected on one side of the crow’s-feet area and a hyaluronic-acid filler on the other. During 12 weeks of follow-up, the main efficacy outcomes showed no statistically significant difference. This was a comparison against hyaluronic acid, not a direct Rejuran-versus-Juvelook trial. These sources do not support claims that Juvelook is twice as strong as Rejuran or that one is universally safer.

A proposed biological mechanism is not the same as demonstrated clinical benefit. Stimulating collagen describes a possible process, not how visibly your face will change. Similarly, supporting repair does not prove that vascular shadows or pores will disappear. If you are promised a precise result or schedule down to the week, ask which study supports that number and whether it evaluated the exact product and body area.

What does recovery mean medically and socially?

Both options involve injections. You may feel needle pricks, stinging or pressure; the amount depends on site, anaesthesia and technique. Afterwards there can be redness, swelling, tiny puncture marks, bumps along injection tracks, bruises and tenderness. Timings differ by formulation and technique, so a promise of no visible marks in 24 hours is unreliable. Superficial microinjections can leave temporary skin irregularities that are particularly apparent at close range.

If tomorrow brings a meeting under strong lights, consider not just when discomfort settles but how comfortable you will feel appearing without concealer. You may not be able to apply makeup immediately over puncture sites; ask the treating clinician. Do not try a new injectable for the first time just before a major event. Exercise, heat treatments, alcohol and vigorous massage belong in a personalised aftercare discussion, not a social-media rule.

Tolerability comparisons are meaningful only for similar areas, depth, puncture count, anaesthesia and injected volume. If one patient received multiple superficial PN passes and another a different solution by a different technique, their swelling and pain reviews cannot show that one brand is intrinsically harsher.

Which risks should not be concealed by the word biostimulation?

Infection, persistent inflammation, nodules, pronounced asymmetry and allergic responses require medical assessment. Vascular injury also matters in facial injections generally, although the frequency and pattern depend on material, tissue plane and technique. The FDA warns about accidental intravascular injection of fillers: sudden unusual pain, whitening or grey-blue skin, visual changes and neurological symptoms demand immediate emergency assistance. This is general injection safety guidance, not proof that Juvelook and Rejuran have identical complication rates.

Active infection, inflamed lesions at the injection site, uncontrolled illness or a previous serious reaction to a constituent require assessment before proceeding. Safety data for elective aesthetic injections in pregnancy and breastfeeding are inadequate, so postponing is prudent. Tell the clinician about medicines, clotting problems, unusual scar formation and all earlier injected materials. Mention any history of fish allergy because PN originates from fish material; this does not mean every such allergy automatically predicts a reaction.

How do you compare clinic offers without confusing doses and promises?

1. Request the full product and version names as printed on the label, manufacturer, components, local regulatory status and batch number. Korean or Australian authorisation does not automatically establish Armenian status.
2. Ask about the exact site and depth and whether the goal is wrinkles, texture, a specific scar or something else. How will improvement be measured?
3. For Juvelook, ask the active quantity in the vial, how it is prepared and the portion actually used. For Rejuran, ask about version, concentration, volume and scheduled visits.
4. Check whether consultations, anaesthesia, all sessions and review are included. Prices per vial, session or millilitre are not comparable without detail.
5. Ask what normal injection marks look like, what happens with a lump and how to obtain urgent help. Do not accept having no complication response plan.
6. If both are proposed together, ask what distinct problem each addresses and what evidence exists for that combination. There is no basis for automatically assuming a combination is better.

A cautious path is entirely valid: first choose appropriate skin care or treatment for an active skin disease, reassess, and only then consider an injection with a clearly defined goal. The useful question is not which brand is fashionable but what measurable change would justify recovery and risk for you. Choosing neither is a complete and legitimate decision.